CFDE Data Portal | Search BNIP3P17

	Label	Description
	BNIP3P17 Gene (Entity type)	ENSG00000271524 - BCL2 interacting protein 3 pseudogene 17
	GSE202434 GSE202438 talazoparib 3 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE176366 vincristine 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE115384 CELSR2 knockdown 5 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 1 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 7 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE217085 L-25 HeLa 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE149768 hypoxanthine 3 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 7 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS

BNIP3P17

ENSG00000271524 - BCL2 interacting protein 3 pseudogene 17

GSE202434 GSE202438 talazoparib 3 v 11 human dn

A Gene Set from LINCS

GSE176366 vincristine 3 v 2 human dn

A Gene Set from LINCS

GSE115384 CELSR2 knockdown 5 v 1 human dn

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 1 v 5 human up

A Gene Set from LINCS

GSE239844 crizotinib 7 v 2 human dn

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 3 v 0 human dn

A Gene Set from LINCS

GSE217085 L-25 HeLa 1 v 0 human up

A Gene Set from LINCS

GSE149768 hypoxanthine 3 v 4 human up

A Gene Set from LINCS

GSE239844 crizotinib 7 v 5 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.